Key result
Omecamtiv mecarbil preserves contractile force but prolongs contraction and relaxation in failing myocardium, reversible by noradrenaline.
Why the study?
To assist translation to clinical practice by investigating the effects of omecamtiv mecarbil on contractile dynamics, interaction with (-)-noradrenaline, and spontaneous contractions in explanted human failing hearts.
Does omecamtiv mecarbil affect contractile dynamics and interact with (-)-noradrenaline in explanted human failing heart trabeculae?
Does omecamtiv mecarbil affect contractile dynamics and interact with (-)-noradrenaline in explanted human failing heart trabeculae?
p-value: p=<0.001
In explanted human failing heart tissue, omecamtiv mecarbil preserves contractile force but causes negative diastolic effects that are reversible with (-)-noradrenaline.
Omecamtiv mecarbil may slow relaxation in failing human myocardium; leaves open net clinical effects pending randomized data.
Omecamtiv mecarbil (OM) is a novel medicine for systolic heart failure, targeting myosin to enhance cardiomyocyte performance. To assist translation to clinical practice we investigated OMs effect on explanted human failing hearts, specifically; contractile dynamics, interaction with the β 1 –adrenoceptor (AR) agonist (−)‐noradrenaline and spontaneous contractions. Left and right ventricular trabeculae from 13 explanted failing hearts, and trabeculae from 58 right atrial appendages of non‐failing hearts, were incubated with or without a single concentration of OM for 120 min. Time to peak force (TPF) and 50% relaxation ( t 50% ) were recorded. In other experiments, trabeculae were observed for spontaneous contractions and cumulative concentration‐effect curves were established to (−)‐noradrenaline at β 1 ‐ARs in the absence or presence of OM. OM prolonged TPF and t 50% in ventricular trabeculae (600 nM, 2 µM, p < .001). OM had no significant inotropic effect but reduced time dependent deterioration in contractile strength compared to control ( p < .001). OM did not affect the generation of spontaneous contractions. The potency of (−)‐noradrenaline (pEC 50 6.05 ± 0.10), for inotropic effect, was unchanged in the presence of OM 600 nM or 2 µM. Co‐incubation with (−)‐noradrenaline reduced TPF and t 50% , reversing the negative diastolic effects of OM. OM, at both 600 nM and 2 µM, preserved contractile force in left ventricular trabeculae, but imparted negative diastolic effects in trabeculae from human failing heart. (−)‐Noradrenaline reversed the negative diastolic effects, co‐administration may limit the titration of inotropes by reducing the threshold for ischemic side effects.
No takes yet. Share an insight, caveat, or question.
Dashwood et al. (2021) studied Systolic heart failure (n=71). Omecamtiv mecarbil (OM) vs. Control (without OM) was evaluated on Time to peak force (TPF) and 50% relaxation (t50%), and contractile strength (p=<0.001). Omecamtiv mecarbil preserved contractile force but prolonged time to peak force and 50% relaxation in human failing ventricular trabeculae (p<0.001), which was reversed by (-)-noradrenaline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: